Objectives: The objectives of this study were to study the presence of mutators in a set of Acinetobacter baumannii isolates and to explore whether there is a correlation between mutation rates and antibiotic resistance.
Introduction
Acinetobacter baumannii is increasingly involved in nosocomial infections, especially in the ICU setting. This pathogen is frequently MDR and has shown a propensity to adapt to the environment through up-regulation of intrinsic resistance and acquisition of antibiotic resistance determinants. 1, 2 Another parameter that modulates the progression of resistance is an increase in general mutation rate (hypermutability), which can influence resistance development through mutation, 3 frequency of lateral gene transfer, 4 up-regulated gene expression and compensatory evolution of a bacterial population. 5 Studies of mutator distribution and level of hypermutability have shown that ≤50% of clinical isolates from a variety of bacterial species exhibit a mutator phenotype/genotype. Many of these mutators are found among infection-causing bacteria, which are isolated from an environment of high selective pressure due to intense antibiotic usage. 6 No previous study has evaluated the existence of mutator isolates in an A. baumannii population, to our knowledge. The aims of this study were to determine the prevalence of mutators in A. baumannii and their hypermutability and to explore whether there is any correlation between changes in the mutation frequency (f) and antibiotic resistance.
Materials and methods

Bacterial isolates, antimicrobials and culture media
Two-hundred-and-thirty-seven A. baumannii isolates originating from Europe, the USA and Sweden between 1990 and 2007 were investigated. 7, 8 A. baumannii ATCC 19606 was chosen as a comparator strain for f assays due to its isolation in 1948 and exposure to less antibiotic selection pressure. The WT Escherichia coli MG1655, E. coli dam (damD 16::Kan r ) and mutS (DmutS::FRT) mutants were used as quality-control strains. 9 All experiments were performed in freshly prepared Mueller-Hinton (MH) broth and MH agar (BD, Sweden); rifampicin was purchased from Sigma-Aldrich, Sweden.
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Susceptibility testing
Resistance profiles were determined using Etest (Biodisk/bioMé rieux, Sweden) and/or disc diffusion (BD/Fisher Scientific, Sweden). The EUCAST clinical breakpoints were used for sorting isolates into antibiotic resistance profile groups (ARPGs) as follows; susceptible, susceptible to all antibiotic groups tested; resistant, resistant to one or two antibiotic groups; and MDR, resistant to three to five antibiotic groups. 10 ARPGs are defined in Table 1 .
Determination of f against rifampicin
To determine f, assays were performed as previously described by Baquero et al. 11 Ten independent cultures for each isolate were grown overnight with shaking, and cells were plated onto MH plates with and without rifampicin (100 mg/L).
The distribution of f values in the population was categorized as previously described (Table 1) . 11, 12 The f values were normalized to control strain ATCC 19606 (f ¼ 7×10 29 ), which was set at 1. Isolates with an ≥2.5-to 10-fold higher f were defined as weak mutators and those with a .10-fold higher f were defined as strong mutators.
Data comparison and statistical methods
Isolates were grouped according to their ARPGs and further into hyponormomutators (f , 2.5-fold) and mutators (f ≥2.5-fold) before analysis. The Mann -Whitney U-test and Kruskal -Wallis analysis of variance (ANOVA) statistical methods were used to compare resistance groups. For associations between ARPG and the number of mutator isolates in each group, the Pearson's x 2 test was used, and logistic regression was used to further investigate the relationship between these variables. P values ,0.05 were considered significant.
Results
Antimicrobial susceptibility profiles
The division of isolates and the percentage of each isolate in each ARPG are shown in Table 1 .
Distribution of f values in bacterial populations
The frequency of rifampicin resistance was determined, and isolates were sorted according to their f, which varied between 2.2×10 210 and 1.2×10 26 ( Figure 1 ). A sharp peak in frequency distribution was found at 10
28
; however, 68% of the population had a lower frequency. To the right of the peak, 15% of the isolates had a moderately higher f, whereas only two isolates (,0.1%) had a frequency .10 27 (Figure 1a ). No A. baumannii isolate displayed hypermutability as high as that of the E. coli mutS strain (f¼ 3×10 26 ), and only one isolate (f ¼ 1.1×10
26
) had a frequency higher than that of the E. coli dam-knockout strain (f ¼ 3.9×10 27 ). When the population was sorted according to their ARPGs, the distribution of the susceptible group showed three peaks, at 2×10 29 ,
6×10
29 and 1×10 28 , respectively, while the frequencies of the resistant group were spread over the whole interval, and for the MDR group, 45% of the isolates were clustered in a sharp peak, with f ranging between 8×10 29 and 2×10 28 (Figure 1b ).
Hypermutability and resistance profile in mutator isolates
Compared with the A. baumannii ATCC 19606 control strain, 200 isolates had an f ranging between 0.03-fold and ,2.5-fold. Of these, 80 were classified as hypomutators (,1.0-fold), composed of 39% susceptible, 19% resistant and 43% MDR isolates, respectively. The overall occurrence of weak and strong mutators Komp Lindgren et al.
was 16%; when the population was divided into ARPGs, the prevalence of mutators in the MDR group (22%) was significantly higher (P,0.05) than the prevalence in the susceptible and resistant groups (11% and 7%, respectively). The geometric mean and median of f for the population and the percentage of mutators in each ARPG are presented in Table 1 . Thirty-seven isolates had an ≥2.5-to 166-fold increase in f (73% with ≥2.5-to 5-fold, 19% with .5-to 10-fold and 8% (Table S1 , available as Supplementary data at JAC Online). Of the mutators, 70% were MDR isolates with a median/ mean increase f of 3.6/11.1-fold (Figure 2a ). There was no significant difference in increased f between the mutators in the susceptible, resistant and MDR groups (P ¼ 0.51 -0.74) (Figure 2a) . However, there was a significant correlation between MDR and increased f (P,0.05) (Figure 2b ). Of the 34 weak mutators, 7, 3 and 24 of the isolates had a susceptible, resistant and MDR phenotype, respectively. All the weak resistant mutators (f 3.19-4.29-fold) were susceptible to cephalosporins and carbapenems, with a varied range of susceptibility to the other ARPGs. Four weak MDR mutators (f 2.51-3.25-fold), which displayed antibiotic resistance to three of five antibiotic groups, were all susceptible to the carbapenem group in combination with susceptibility to either the tetracycline-like, aminoglycoside or fluoroquinolone group of antibiotics. Of the remaining 20 weak MDR isolates, nine were resistant to all antibiotic groups (f 3.14-8.29-fold), 5 were resistant to all except tetracycline-like antibiotics (f 2.57 -5.89-fold) and 6 were resistant to all except carbapenem-group antibiotics (f 2.71-10.0-fold) ( Table S1 ).
The remaining three strong mutators, one susceptible isolate and two MDR isolates, displayed 11.1-fold (AB95), 19.5-fold (AB279) and 166-fold (AB190) increased f (Table S1 ). In comparison with the control mutator E. coli strains (dam and mutS mutants, 55.7-and 429-fold increased f), the AB190 isolate can be regarded as a strong mutator.
Discussion
This study is the first one, to our knowledge, on the occurrence of mutators in an A. baumannii population, and we have shown that 16% of isolates from our collection displayed an ≥2.5-to 166-fold increase in f. The prevalence of mutators and their f values were significantly higher in the MDR group compared with those of the susceptible and resistant groups. We also found 0.42% and 15.2% of isolates to be strong and weak mutators, respectively, which are around the same range as findings for E. coli urinary tract isolates, where the proportions were 0.5% -1% and 25% -40% for strong and weak mutators, respectively. 11, 13 Variation in mutation rates and its effect on resistance development and bacterial adaptability have been studied extensively over recent years. It was shown that even a small (2 -4-fold) increase in mutation rate can drive the evolution of fluoroquinolone resistance, and, furthermore, a slight increase in f favours the evolution of MDR. 9, 14 In E. coli, selection with rifampicin and ciprofloxacin showed that mutator strains generated both higher resistance levels and resistance mutations with ≤1000-fold higher f.
15
Studies of clinical isolates have revealed that weak mutators can be present at earlier stages of infection, and a modestly elevated mutation rate can give them an adaptive advantage. 16 Another aspect of mutators is the notion that some genotypes can exhibit increased frequency of recombination, interspecies recombination and transformation. 17, 18 These events might explain in part the ability of A. baumannii to adapt, whereby a mutator can integrate DNA that carries resistance markers and/or increase the chance of gaining mutations that promote the survival of the organism in clinical settings.
Carbapenems are still the drugs of choice to treat A. baumannii infections, even though resistance rates are increasing. 1 To understand the progression of carbapenem resistance, Zander et al. 19 investigated three isolates recovered from patients during an outbreak in a hospital in Krakow, Poland. Sequencing of bla OXA 51-like genes showed that carbapenem resistance was caused by a conversion of OXA-66 into OXA-82 and that bla OXA-82 was also associated with the IS element ISAba1. A second study looked at related isolates possessing similar plasmids that encode the carbapenemase OXA-58 and exhibit varying levels of carbapenem resistance. Sequencing revealed genetic variability composed of multiple copies of the bla OXA 58 gene and that extra copies were due to IS-element transposition or recombination events. 20 These adaptive modifications could be elevated in a population composed of mutators, where hypermutability can drive the progression of survival and evolution of genetic elements such as b-lactamase genes. However, whether any of the genetic changes seen in these studies was due to an altered mutation rate is not known.
In conclusion, we have shown that 16% of the A. baumannii strains were weak-to-strong mutators and that there was a strong correlation with an increased f with an MDR phenotype. The fact that a high percentage of MDR A. baumannii isolates show an increased mutability in clinical settings calls for further studies that could form the basis of novel treatment strategies.
